http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Twist Bioscience Corporation (TWST) Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software
-
Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software
-
AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests
-
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
-
Twist Bioscience Earns 2021 Great Place to Work Certification™
-
Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
-
Twist Bioscience Corporation (TWST) , Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay
-
Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay
-
Twist Bioscience (TWST) Functional GLP-1R Antibodies Identified From Its Proprietary Synthetic DNA GPCR Libraries Demonstrate Potent Blood Glucose Control
-
Twist Bioscience Functional GLP-1R Antibodies Identified From Its Proprietary Synthetic DNA GPCR Libraries Demonstrate Potent Blood Glucose Control
-
Twist Bioscience (TWST) Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants
-
Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants
-
Twist Bioscience Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021
-
Twist Bioscience (TWST) and Watchmaker Genomics Announce Partnership to Drive New Applications of High-throughput Genetic Sequencing
-
Twist Bioscience and Watchmaker Genomics Announce Partnership to Drive New Applications of High-throughput Genetic Sequencing
-
Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT
-
Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
-
Twist Bioscience Launches Industry-Leading NGS Methylation Detection System for Liquid Biopsy Cancer Analysis and Epigenetic Studies
-
Cathie Wood's ARK Bought Buys ~$200M More Tesla (TSLA) Monday on Sell-Off
-
Twist Bioscience and Berry Genomics to Offer New NGS Solution to Advance Research and Precision Medicine
-
Twist Bioscience to Present at Upcoming Virtual Conferences
-
Twist Bioscience (TWST) and Victorian Clinical Genetic Services Collaborate on Development of Novel Whole Exome Capture Diagnostic Assay
-
Twist Bioscience and Victorian Clinical Genetic Services Collaborate on Development of Novel Whole Exome Capture Diagnostic Assay
-
Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth
-
Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results
-
Twist Bioscience Announces Executive Team Appointments
-
Twist Bioscience to Report Fiscal 2021 First Quarter Financial Results on Thursday, February 4, 2020
-
Twist Bioscience Corporation (TWST) Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discovery
-
Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discovery
-
Twist Bioscience Corporation (TWST) Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2
-
Twist Bioscience Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2
-
Twist Bioscience (TWST) Supplies Centers for Disease Control and Prevention with Custom SARS-CoV-2 Synthetic RNA Controls
-
Twist Bioscience Supplies Centers for Disease Control and Prevention with Custom SARS-CoV-2 Synthetic RNA Controls
-
Twist Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Twist Bioscience Corporation (TWST) to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2
-
Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2
-
Twist Bioscience to Expand Commercial Capabilities with Factory of the Future
-
Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments
-
Twist Bioscience to Present at Upcoming Virtual Investor Conferences
-
Twist Bioscience Corporation (TWST) Reports Positive Preclinical Data for SARS-CoV-2 Antibodies
-
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results
-
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
-
Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
-
Twist Bioscience Ranked 60th Fastest Growing Company in North America on Deloitte’s 2020 Fast 500™
-
Twist Bioscience Expands Infectious Disease Product Line Adding Comprehensive Viral Panel
-
Twist Bioscience Continues Support for Next Generation of Synthetic Biologists Through Work with iGEM Competition
-
Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA
-
Twist Bioscience to Present at the Stifel 2020 Virtual Healthcare Conference
-
Twist Bioscience to Report Fiscal 2020 Fourth Quarter and Full Year Financial Results on Monday, November 23, 2020
-
Twist Bioscience Showcases Next-Generation Sequencing Presentations at Virtual American Society for Human Genetics 2020 Annual Meeting
